A Novel Multiplex Cell Viability Assay for High-Throughput RNAi Screening

Cell-based high-throughput RNAi screening has become a powerful research tool in addressing a variety of biological questions. In RNAi screening, one of the most commonly applied assay system is measuring the fitness of cells that is usually quantified using fluorescence, luminescence and absorption-based readouts. These methods, typically implemented and scaled to large-scale screening format, however often only yield limited information on the cell fitness phenotype due to evaluation of a single and indirect physiological indicator. To address this problem, we have established a cell fitness multiplexing assay which combines a biochemical approach and two fluorescence-based assaying methods. We applied this assay in a large-scale RNAi screening experiment with siRNA pools targeting the human kinome in different modified HEK293 cell lines. Subsequent analysis of ranked fitness phenotypes assessed by the different assaying methods revealed average phenotype intersections of 50.7±2.3%–58.7±14.4% when two indicators were combined and 40–48% when a third indicator was taken into account. From these observations we conclude that combination of multiple fitness measures may decrease false-positive rates and increases confidence for hit selection. Our robust experimental and analytical method improves the classical approach in terms of time, data comprehensiveness and cost.

[1]  H. Pijl,et al.  Systemic energy homeostasis in Huntington's disease patients , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[2]  D. Ehrnhoefer,et al.  EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.

[3]  A. Tolkovsky,et al.  Cytoplasmic Inclusions of Htt Exon1 Containing an Expanded Polyglutamine Tract Suppress Execution of Apoptosis in Sympathetic Neurons , 2008, The Journal of Neuroscience.

[4]  D. Melton,et al.  Replication and episomal maintenance of Epstein-Barr virus-based vectors in mouse embryonal fibroblasts enable synthetic lethality screens. , 2003, Molecular cancer therapeutics.

[5]  L. Neckers,et al.  Hsp90 phosphorylation, Wee1 and the cell cycle , 2010, Cell cycle.

[6]  J. Lucas,et al.  Nuclear localization of N‐terminal mutant huntingtin is cell cycle dependent , 2002, The European journal of neuroscience.

[7]  G. Hampton,et al.  RNAi and HTS: exploring cancer by systematic loss-of-function , 2004, Oncogene.

[8]  R. Larsson,et al.  A rapid fluorometric method for semiautomated determination of cytotoxicity and cellular proliferation of human tumor cell lines in microculture. , 1989, Anticancer research.

[9]  J. Olson,et al.  Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration , 2007, PLoS genetics.

[10]  Jeffrey C. Erlich,et al.  Phospholipid‐Metabolizing Enzymes in Alzheimer's Disease: Increased Lysophospholipid Acyltransferase Activity and Decreased Phospholipase A2 Activity , 1998, Journal of neurochemistry.

[11]  D. Silver,et al.  Synthetic lethality--a new direction in cancer-drug development. , 2009, The New England journal of medicine.

[12]  D. Rubinsztein,et al.  Glycogen Synthase Kinase-3β Inhibitors Prevent Cellular Polyglutamine Toxicity Caused by the Huntington's Disease Mutation* , 2002, The Journal of Biological Chemistry.

[13]  N. Déglon,et al.  Implication of the JNK pathway in a rat model of Huntington's disease , 2009, Experimental Neurology.

[14]  Edoardo Marcora,et al.  The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus. , 2010, Human molecular genetics.

[15]  L. Cope,et al.  Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc , 2010, Oncogene.

[16]  M. Giacomello,et al.  Huntington's disease, calcium, and mitochondria. , 2011, BioFactors.

[17]  M. MacDonald,et al.  Identification of compounds which inhibit cytotoxicity associated with mutant Huntingtin protein expression , 2011 .

[18]  S. Humbert,et al.  Mutant huntingtin‐impaired degradation of β‐catenin causes neurotoxicity in Huntington's disease , 2010, The EMBO journal.

[19]  R. Holcombe,et al.  Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. , 2010, International journal of molecular medicine.

[20]  Oliver Pelz,et al.  web cellHTS2: A web-application for the analysis of high-throughput screening data , 2010, BMC Bioinformatics.

[21]  M. Loureiro-Dias,et al.  Flow Cytometric Assessment of Membrane Integrity of Ethanol-Stressed Oenococcus oeni Cells , 2002, Applied and Environmental Microbiology.

[22]  Michael Boutros,et al.  High‐throughput RNAi screening to dissect cellular pathways: A how‐to guide , 2010, Biotechnology journal.

[23]  A. Giaccia,et al.  Harnessing synthetic lethal interactions in anticancer drug discovery , 2011, Nature Reviews Drug Discovery.

[24]  Nick S. Jones,et al.  Connecting Variability in Global Transcription Rate to Mitochondrial Variability , 2010, PLoS biology.

[25]  I. Vincent,et al.  Constitutive Wee1 activity in adult brain neurons with M phase-type alterations in Alzheimer neurodegeneration. , 2001, Journal of Alzheimer's disease : JAD.

[26]  M. Adolphe,et al.  A non-isotopic, highly sensitive, fluorimetric, cell-cell adhesion microplate assay using calcein AM-labeled lymphocytes. , 1995, Journal of immunological methods.

[27]  M. Chiang,et al.  The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. , 2011, Biochimica et biophysica acta.

[28]  Matthew D. Ringel,et al.  The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors , 2010, Molecular and Cellular Endocrinology.

[29]  B. Gatto,et al.  DNA minor groove-binding ligands: a different class of mammalian DNA topoisomerase I inhibitors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Earnest,et al.  Circadian rhythms of extracellular ATP accumulation in suprachiasmatic nucleus cells and cultured astrocytes , 2009, The European journal of neuroscience.

[31]  F. Ataullakhanov,et al.  What Determines the Intracellular ATP Concentration , 2002, Bioscience reports.

[32]  J. Olson,et al.  PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. , 2009, Cancer research.

[33]  J. Caviston,et al.  Huntingtin coordinates the dynein-mediated dynamic positioning of endosomes and lysosomes , 2011, Molecular biology of the cell.

[34]  G. Johnson,et al.  The interrelationship between mitochondrial dysfunction and transcriptional dysregulation in Huntington disease , 2010, Journal of bioenergetics and biomembranes.